- Jazz Pharmaceuticals (NASDAQ:JAZZ) will host a virtual investor event on Monday, October 26, at 4:30 pm ET to discuss the commercial launch of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, approved in the U.S. in July for cataplexy (excessive daytime sleepiness) in patients at least seven years old with narcolepsy.
- The launch should commence in early November.
- https://seekingalpha.com/news/3623424-jazz-pharma-investor-event-october-26-on-xywav-launch
Monday, October 19, 2020
Jazz Pharma investor event October 26 on Xywav launch
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.